Marksans Pharma Limited
Символ: MARKSANS.NS
NSE
172.15
INRПазарна цена днес
24.5829
Съотношение P/E
0.5835
Коефициент PEG
78.01B
MRK Cap
- 0.00%
Доходност на DIV
Marksans Pharma Limited (MARKSANS-NS) финансови отчети
Баланс
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 27678.4 | 7191.6 | 3466.9 | 2093.8 | |||||||||||||||||||
balance-sheet.row.short-term-investments | 34038.7 | 3367.2 | 4.3 | 17.2 | |||||||||||||||||||
balance-sheet.row.net-receivables | 8696.08 | 4187.6 | 4115.6 | 2767.3 | |||||||||||||||||||
balance-sheet.row.inventory | 10153.42 | 4847.4 | 4244.4 | 4043.2 | |||||||||||||||||||
balance-sheet.row.other-current-assets | 1029.74 | 526.4 | 185.1 | 118.2 | |||||||||||||||||||
balance-sheet.row.total-current-assets | 47557.64 | 16753 | 12012 | 9022.5 | |||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 8581.34 | 3868.9 | 3422.9 | 2540.2 | |||||||||||||||||||
balance-sheet.row.goodwill | 771.91 | 384.9 | 300.3 | 195.9 | |||||||||||||||||||
balance-sheet.row.intangible-assets | 1395.4 | 708 | 585.7 | 474.4 | |||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 2167.31 | 1092.9 | 885.9 | 670.2 | |||||||||||||||||||
balance-sheet.row.long-term-investments | -6433 | -3332.4 | -62 | 8.4 | |||||||||||||||||||
balance-sheet.row.tax-assets | 6517.3 | 3375.9 | 38.6 | 8 | |||||||||||||||||||
balance-sheet.row.other-non-current-assets | -13350.95 | 145.7 | 103.7 | 33.2 | |||||||||||||||||||
balance-sheet.row.total-non-current-assets | -2518 | 5150.9 | 4389 | 3260 | |||||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||||||
balance-sheet.row.total-assets | 45039.64 | 21903.9 | 16401 | 12282.5 | |||||||||||||||||||
balance-sheet.row.account-payables | 4309.35 | 2306 | 2000.8 | 1686.6 | |||||||||||||||||||
balance-sheet.row.short-term-debt | 1073.1 | 572.6 | 693.4 | 247.8 | |||||||||||||||||||
balance-sheet.row.tax-payables | 667.33 | 252.8 | 173.3 | 300.2 | |||||||||||||||||||
balance-sheet.row.long-term-debt-total | 1267.38 | 656.9 | 414.3 | 93.3 | |||||||||||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 121.1 | |||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 321.13 | - | - | - | |||||||||||||||||||
balance-sheet.row.other-current-liab | 376.6 | 112.4 | 543 | 639.3 | |||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 1681.51 | 843.3 | 609.1 | 245 | |||||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 1572.51 | 813.6 | 694.9 | 153.6 | |||||||||||||||||||
balance-sheet.row.total-liab | 8418.8 | 4253.2 | 4171.3 | 3229 | |||||||||||||||||||
balance-sheet.row.preferred-stock | 13274.17 | 13274.2 | 0 | 0 | |||||||||||||||||||
balance-sheet.row.common-stock | 906.32 | 453.2 | 409.3 | 409.3 | |||||||||||||||||||
balance-sheet.row.retained-earnings | 10913.4 | 10913.4 | 5093.1 | 3349.3 | |||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 58687.73 | 4177.4 | 4788.4 | 3355 | |||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | -10953.25 | -11366.6 | 1731.9 | 1751.3 | |||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 72828.37 | 17451.6 | 12022.7 | 8864.9 | |||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 81660.48 | 21903.9 | 16401 | 12282.5 | |||||||||||||||||||
balance-sheet.row.minority-interest | 413.31 | 199.1 | 207 | 188.6 | |||||||||||||||||||
balance-sheet.row.total-equity | 73241.68 | 17650.7 | 12229.7 | 9053.5 | |||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 81660.48 | - | - | - | |||||||||||||||||||
Total Investments | 27605.7 | 34.8 | 26.1 | 25.6 | |||||||||||||||||||
balance-sheet.row.total-debt | 2340.48 | 1229.5 | 1107.8 | 341 | |||||||||||||||||||
balance-sheet.row.net-debt | 8700.78 | -2594.9 | -2354.8 | -1752.8 |
Отчет за паричните потоци
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 3181.21 | 3376.5 | 2475.1 | 3021.6 | |||||||||||||||||
cash-flows.row.depreciation-and-amortization | 671.58 | 518.5 | 447.8 | 361.5 | |||||||||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.stock-based-compensation | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.change-in-working-capital | 0 | -1114.7 | -1107 | -1500.3 | |||||||||||||||||
cash-flows.row.account-receivables | 0 | -275.2 | -1039.3 | -367.4 | |||||||||||||||||
cash-flows.row.inventory | 0 | -448.5 | -178.5 | -1624.8 | |||||||||||||||||
cash-flows.row.account-payables | 0 | 224.2 | 184.9 | 417.8 | |||||||||||||||||
cash-flows.row.other-working-capital | 0 | -615.2 | -74.1 | 74.1 | |||||||||||||||||
cash-flows.row.other-non-cash-items | -3181.21 | -406.3 | -823.3 | -95.5 | |||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 1343.16 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -536.3 | -463.3 | -464.2 | |||||||||||||||||
cash-flows.row.acquisitions-net | 0 | -266.1 | 0.3 | 5.2 | |||||||||||||||||
cash-flows.row.purchases-of-investments | 0 | -1897.7 | -1.5 | 0 | |||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 2163.8 | -0.3 | 0 | |||||||||||||||||
cash-flows.row.other-investing-activites | 0 | -2055.8 | 47.9 | 10.1 | |||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -2592.1 | -416.9 | -449 | |||||||||||||||||
cash-flows.row.debt-repayment | 0 | -2295.4 | -225.5 | -1 | |||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 2747.1 | 911.5 | 0 | |||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | -451.7 | -225.5 | 0 | |||||||||||||||||
cash-flows.row.dividends-paid | 0 | -101.7 | -105.8 | -40.9 | |||||||||||||||||
cash-flows.row.other-financing-activites | 0 | 2080 | 440.4 | -110.9 | |||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 1978.3 | 795.1 | -152.9 | |||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | -1428.6 | -1 | |||||||||||||||||
cash-flows.row.net-change-in-cash | 1343.16 | 1760.3 | 1370.8 | 1185.6 | |||||||||||||||||
cash-flows.row.cash-at-end-of-period | 21580.94 | 3824.4 | 3492.7 | 2122.9 | |||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 20237.78 | 2064.1 | 2121.8 | 937.3 | |||||||||||||||||
cash-flows.row.operating-cash-flow | 1343.16 | 2374.1 | 992.6 | 1787.4 | |||||||||||||||||
cash-flows.row.capital-expenditure | 0 | -536.3 | -463.3 | -464.2 | |||||||||||||||||
cash-flows.row.free-cash-flow | 1343.16 | 1837.8 | 529.3 | 1323.2 |
Ред за отчет за приходите
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 21033.72 | 18521.4 | 14801.2 | 13683.7 | |||||||||||||||||||
income-statement-row.row.cost-of-revenue | 10121.39 | 9213.6 | 7480.2 | 6186 | |||||||||||||||||||
income-statement-row.row.gross-profit | 10912.33 | 9307.8 | 7321.1 | 7497.8 | |||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||||||
income-statement-row.row.research-development | 283.89 | - | - | - | |||||||||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||||||
income-statement-row.row.other-expenses | 449.01 | 593.1 | 95.6 | 38.7 | |||||||||||||||||||
income-statement-row.row.operating-expenses | 6999.05 | 6433.1 | 5153.7 | 4310.6 | |||||||||||||||||||
income-statement-row.row.cost-and-expenses | 17120.44 | 15646.7 | 12633.9 | 10496.6 | |||||||||||||||||||
income-statement-row.row.interest-income | 158.31 | 59.4 | 59.7 | 11.6 | |||||||||||||||||||
income-statement-row.row.interest-expense | 88.03 | 91.3 | 53.9 | 34.7 | |||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 12.93 | 499.2 | 334.1 | -70.6 | |||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||||||
income-statement-row.row.other-operating-expenses | 449.01 | 593.1 | 95.6 | 38.7 | |||||||||||||||||||
income-statement-row.row.total-operating-expenses | 12.93 | 499.2 | 334.1 | -70.6 | |||||||||||||||||||
income-statement-row.row.interest-expense | 88.03 | 91.3 | 53.9 | 34.7 | |||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 671.58 | 518.5 | 447.8 | 361.5 | |||||||||||||||||||
income-statement-row.row.ebitda-caps | 5033.87 | - | - | - | |||||||||||||||||||
income-statement-row.row.operating-income | 4261.33 | 2877.3 | 2141 | 3092.2 | |||||||||||||||||||
income-statement-row.row.income-before-tax | 4274.26 | 3376.5 | 2475.1 | 3021.6 | |||||||||||||||||||
income-statement-row.row.income-tax-expense | 1074.63 | 723.3 | 607 | 636.3 | |||||||||||||||||||
income-statement-row.row.net-income | 3173.43 | 2663.1 | 1845.7 | 2385.4 |
Често задавани въпроси
Какво е Marksans Pharma Limited (MARKSANS.NS) общи активи?
Marksans Pharma Limited (MARKSANS.NS) общите активи са 21903890000.000.
Какъв е годишният приход на предприятието?
Годишните приходи са 11173630000.000.
Какъв е маржът на печалбата на предприятието?
Маржът на печалбата на фирмата е 2.964.
Какъв е свободният паричен поток на компанията?
Свободният паричен поток е 2.964.
Какъв е маржът на нетната печалба на предприятието?
Маржът на нетната печалба е 0.151.
Какъв е общият приход на предприятието?
Общият приход е 0.203.
Каква е Marksans Pharma Limited (MARKSANS.NS) нетна печалба (нетен доход)?
Нетната печалба (нетният доход) е 2663080000.000.
Какъв е общият дълг на фирмата?
Общият дълг е 1229450000.000.
Какъв е броят на оперативните разходи?
Оперативните разходи са 6433130000.000.
Какъв е броят на паричните средства на фирмата?
Паричните средства на предприятието са -6611350000.000.